The invention relates to a drug delivery device, and more particularly to an interchangeable nebulizer mouthpiece for delivering drugs to a patient.
Drugs and other substances can be administered to a patient through a variety of methods. For example, one method includes intravenous injection where the drug or substance is injected into a person's veins. Another method includes a sublingual delivery system where the drug or substance is placed under the user's tongue and is allowed to be absorbed through the mucus membranes of the mouth. Still another method of drug or substance delivery includes applying the drug or substance directly onto the recipient's skin where it either treats a condition on the surface of the skin or is absorbed into the body.
One method of administering a drug or substance to a patient suffering from respiratory as well as other conditions includes inhaling gas carrier or a gas in which a drug or other substance is dissolved, mixed, entrained, suspended or otherwise incorporated into the gas carrier or gas. With this delivery method, the gas carrier or gas functions as a gas carrier which carries the drug or substance into the user's lungs where is may be absorbed to treat a condition of the lungs or in some instances be transferred into the circulation system of the user to be distributed throughout the body.
It should be noted that although a drug is typically the material which is delivered in this way, virtually any chemical or substance either in a gaseous, liquid, or solid form may be delivered using this inhalation technique. Furthermore, the gas carrier which is typically gas carrier may also be made up only of, or partially of, any kind of gas or mixture of gases where the gas or mixture of gases serves to not only transport the drug or substance into the users lungs, but may also interact with the users tissues as well as interact with the drug or substance being delivered. Such interaction may further enhance the chemical or medical activity of the drug or substance, as well as suppress or enhance certain responses of the tissue to the drug or substance to be delivered.
The drug or substance to be delivered can be incorporated into the gas carrier, which will be referred to as gas carrier hereinafter for simplicity, through a variety of methods. For example, the drug can take the form of a gas and be mixed into the gas carrier and remain suspended in the gas carrier, or dissolved in the gas carrier. Additionally, the delivered substance may exist initially in the form of a bulk liquid and be converted to small droplets or a mist which is mixed or entrained into the gas carrier for transport into the lungs. Furthermore, the delivered substance may be converted from a liquid into a vapor through heating, for example, for incorporation into the gas carrier. Also, the delivered substance may exist in solid form as particles which are mixed, entrained, or otherwise suspended in the gas carrier while the gas carrier is inhaled by the user.
Because the delivered substance may exist in a variety of forms all of which have different degrees of ease of incorporation into the gas carrier flowing into a user's lungs, an efficient means for incorporating the delivered substance into the gas carrier is needed. A typical way of incorporating the delivered substance into a gas carrier is an aerosolization chamber, or nebulizer.
Additionally, the delivered substance can exist in a first form which is then mixed with a carrier substance such as mixing solid particles into a liquid and the resulting liquid-particle mixture is then converted into a mist and incorporated into the gas carrier.
Typically, a nebulizer uses the flow of the gas carrier through a chamber to cause turbulence between the gas carrier and the substance at their interface in order to form a mixture of the substance and gas carrier, the delivered substance is then carried into the user's lungs along a flow path from the mixing area to the user's mouth or nose.
Accordingly, mouthpiece is typically joined to the nebulizer which is then inserted into the patient's mouth during inhalation through the mouth. As such, as the user inhales, the gas carrier is drawn through the mouthpiece and through the nebulizer which initiates the mixing of the delivered substance in the gas carrier.
Because some delivered substances may be difficult to incorporate into a gas carrier, and other delivered substances must be delivered at dosage rates which require the gas carrier to carry a large amount of the delivered substance, it is important that the nebulizer and mouthpiece work to efficiently mix the delivered substance into the gas carrier. Furthermore, because some patients being treated using this inhalation technique are in a weakened or otherwise impgas carriered condition and cannot inhale the gas carrier with a force sufficient to power the mixing process in the nebulizer, efficient mixing is advantageous.
For the above stated reasons, a mouthpiece is needed which can be attached to a variety of nebulizers which makes efficient use of a gas carrier passing through the mouthpiece and nebulizer to easily incorporate a delivered substance into the gas carrier flow. Furthermore, a mouthpiece which directs gas carrier into and out of a nebulizer in such a way as to efficiently mix a delivered substance into the inhaled gas carrier is needed. Also, a mouthpiece which aids in efficiently mixing a delivered substance into a gas carrier and a nebulizer, and which will attach to a variety of nebulizer styles from various manufacturers is needed.
These and other drawbacks may be present.
The invention may address these and other drawbacks.
An aspect of the invention provides a nebulizer with interchangeable caps that allow for use with a patient mouthpiece and with a ventilator line.
Another aspect of the invention provides a nebulizer that reduces spillage when tipped over.
According to an aspect of the invention, a breath enhanced device is provided, including a delivery conduit, a cap, and a plurality of cylinders, where the plurality of cylinders are attached to the cap so that when the cap is attached to a container, a liquid within the container is prevented from flowing through the drug delivery conduit when the cap is in a first position.
The plurality of cylinders may include an inner cylinder, an outer cylinder and an intermediate cylinder located between the outer cylinder and the inner cylinder. The inner cylinder and the outer cylinder may have substantially the same height in relation to the cap, and the intermediate cylinder may have a different height in relation to the cap. The device also may include a hollow chamber having two openings, wherein at least one of the plurality of cylinders may attach the cap to the hollow container at the at least one opening and wherein the liquid may be contained in the hollow chamber. The second opening may be attached to a gas carrier flow so that at least a portion of the liquid is aerosolized into the gas carrier flow and the aerosolized gas carrier flow may be delivered to a subject through the delivery conduit. The liquid may be a drug, or a solution including an active ingredient, such as an anti-inflammatory or an anti-infective.
Another aspect of the invention provides a device for delivery of a compound that includes a hollow body having an airflow inlet for receiving a gas carrier flow and an opening, the hollow body containing a liquid, an aerosol insert interacting with the hollow body to aerosolize the liquid into the gas carrier flow, where the aerosol insert is separate and removable from the hollow body, and a cap including a delivery conduit for directing the aerosolized liquid and the gas carrier, where the cap is separate and removable from the hollow body and the aerosol insert.
The cap may direct the aerosolized liquid and the gas carrier to a mouthpiece, or into a ventilator gas carrier flow. The cap may direct the aerosolized liquid and the gas carrier flow into a subject's lungs. The liquid may be a drug and/or a solution. The solution may include an active ingredient, such as an anti-inflammatory or an anti-infective.
Another aspect of the invention provides a device for delivery of a compound that includes a container holding the compound, the container including an insert and receiving a gas carrier and where the gas carrier interacts with the insert to form a mixture of the gas carrier and the compound. The device also includes a cap having a first cap opening and a second cap opening, the first cap opening engaging said container holding the compound. The device further includes a connector having a first container opening connected to the second cap opening, and a second container opening cooperating to direct the mixture.
The connector may direct the aerosolized liquid and the gas carrier to a mouthpiece. The gas carrier may be received from a ventilator. The connector may direct the mixture into a subject's lungs. The liquid may be a drug and/or a solution. The solution may include an active ingredient, such as an anti-inflammatory or an anti-infective.
Additionally features, advantages, and embodiments of the invention may be set forth or apparent from consideration of the following detailed description, drawings and claims. Moreover, it is to be understood that both the foregoing summary of the invention and the following detailed description are exemplary and intended to provide further explanation without limiting the scope of the invention claimed.
The accompanying drawings, which are included to provide a further understanding of the invention, are incorporated in and constitute a part of this specification, illustrate embodiments of the invention and together with the detailed description serve to explain the principles of the invention. No attempt is made to show structural details of the invention in more detail than may be necessary for a fundamental understanding of the invention and the various ways in which it may be practiced. In the drawings:
The embodiments of the invention and the various features and advantageous details thereof are explained more fully with reference to the non-limiting embodiments and examples that are described and/or illustrated in the accompanying drawings and detailed in the following description. It should be noted that the features illustrated in the drawings are not necessarily drawn to scale; and features of one embodiment may be employed with other embodiments as the skilled artisan would recognize, even if not explicitly stated herein. Descriptions of well-known components and processing techniques may be omitted so as to not unnecessarily obscure the embodiments of the invention.
The examples used herein are intended merely to facilitate an understanding of ways in which the invention may be practiced and to further enable those of skill in the art to practice the embodiments of the invention. Accordingly, the examples and embodiments herein should not be construed as limiting the scope of the invention, which is defined solely by the appended claims and applicable law. Moreover, it is noted that like reference numerals represent similar parts throughout the several views of the drawings.
Referring now to the drawings,
The drug delivery port 16 defines both an outlet and an inlet into a top flow path. The top flow path at the drug delivery port 16 can be defined as an outflow path 26 upon inhalation and an inflow path 28 upon exhalation, both moving gas carrier through the same volume of drug delivery conduit 14 and through the drug delivery port 16 at different times depending upon whether the patient is inhaling or exhaling.
The hollow body 12 has a connection port 40 or opening at its lower end. Within the hollow body 12 is a baffle 42 which can either be planer, circular, tubular, etc. Together, the hollow body 12 and the baffle 42 define two gas carrier flow paths within the hollow body 12. For example, in
More specifically, the gas carrier flow path through the hollow body 12 may be subdivided into sections. Accordingly, upon inhalation, the gas carrier flow path through the interior of the baffle 42 may include an intake flow path 32, also referred to as a nebulizer inflow path. The gas carrier flow path 32 within the baffle 42 may also include an exhaust gas carrier flow path 24 which occupies the same volume within the baffle 42 upon exhalation. The baffle 42 and the hollow body 12 also define an gas carrier flow path therebetween which include a drug delivery flow path 22, also referred to as an outflow path. Also included in the same volume as this gas carrier flow path is an exhaust flow path 30.
The hollow body 12 has a top which includes a vent 21. The vent 21 may be configured to be selectively sealable. The vent 21 defines one or more gas carrier flow paths through the top of the hollow body 12 including an intake flow path 34 and an exhaust flow path 36. Where the baffle 42 is a conduit, the vent 21 may communicate with an end of that conduit. The hollow body 12 may also include a handle 44 configured to aid in grasping the breath enhanced mouthpiece 10.
In this embodiment of the breath enhanced mouthpiece 10, the drug delivery conduit 14 joins the hollow body 12 at an angle of less than 90 degrees as referenced to the top of the hollow body 12. It should be noted that the drug delivery conduit 14 may join the hollow body 12 at substantially any angle desired, and is preferably configured to be joined at an angle configured for ease of insertion into a user's mouth.
Thus the entire flow path upon inhalation includes flow paths of 22, 26, 32, and 34 of
As shown in
Referring to
As shown in
The breath enhanced mouthpiece 10 also defines a second gas carrier flow path also referred to as an exhaust gas carrier flow path 50 represented by the hollow, arrows. It should be noted the exhaust gas carrier flow path 50 may flow along the same volume of flow as the intake flow path 48, however, in the opposite direction thereto and at different times during use of the mouthpiece 10. Accordingly, the exhaust gas carrier flow path 50 flows along a path from the drug delivery port 16 down through the interior of the drug delivery conduit 14 and through the union inlet 46. The exhaust flow path 50 enters the hollow body 12 and flows through the hollow body 12 along the outside of the baffle 42 towards the bottom of the baffle 42. The exhaust flow 50 then enters the bottom of the baffle 42 and flows towards the top of the hollow body 12. Proximate the top of the baffle 42 and hollow body 12, the exhaust flow path 50 exits the hollow body 12 through a vent 21. As can be seen, the intake flow path 48 and the exhaust flow path 50 are substantially along the same path, but opposite of one another.
Referring to
As shown in
Referring to
Referring to
Referring to
The drug delivery conduit 104 includes a user interface 106 and an opening which defines a drug delivery port 108. Vent conduit 110 includes a selectively sealable vent 112 on an end. The hollow body 102 includes a connection port 116 at a lower end of the hollow body 102. Disposed within the hollow body 102 and protruding from the hollow body 102 through the drug connection port 116 is a baffle 114. Although
The breath enhanced mouthpiece 100 also includes multiple vents on an end of the vent conduit 110. The vent includes a selectively sealable inlet vent 112 and selectively sealable outlet vents 120. Also included on the end of the vent conduit 110 is a diaphragm retainer 122 which is configured to hold a diaphragm on the end of the vent conduit 110.
Referring to
Referring to
The structure of the breath enhanced mouthpiece 100 is configured to define various gas carrier flow paths therein. For example, one of the flow paths includes a delivery flow path 130. The delivery flow path 130 may begin at the selectively sealable inlet vent 112 and pass between both walls 128 in the interior of the vent conduit 110. Proximate the union 118, the delivery flow path 130 turns and enters the baffle 114 and passes through the interior of the baffle 114 and out the baffle's lower end. At this point, the delivery flow path 130 may pass through an aerosolization or nebulizing area where drugs or other substances in the forms a gas, a vapor, or small particles or droplets may be entrained, mixed or otherwise incorporated into the gas carrier passing along the flow path 130. The delivery flow path 130 then proceeds along the exterior of the baffle 114 towards the union 118. The delivery flow path 130 enters the drug delivery conduit 104 proximate the union 118, and proceeds along the drug delivery conduit 104 to exit therefrom through the drug delivery port 108.
The breath enhanced mouthpiece 100 includes other flow paths through its interior. For example, an exhaust flow path 131 may include a path from the drug delivery port 108 and through the drug delivery port 104. Proximate the union 118, the exhaust flow path 131 passes into the vent conduit 110 and divides into two paths. Each path passes between a wall 128 and the interior wall of the vent conduit 110. The exhaust flow path 131 then exits the breath enhanced mouthpiece 100 through the selectively sealable output vents 120 past the diaphragm 119.
Referring to
The drug delivery conduit 204 includes a mouthpiece 206 and a port 208 at an end of the drug delivery conduit 204. Proximate to where the hollow body 202 and drug delivery conduit 204 join at the union 212, is an exhaust aperture 221 covered by a diaphragm 218. The exhaust aperture 221 is located near the top of the hollow body 202. On the exterior of the hollow body 202 near the exhaust aperture 221 is a protrusion 216, which may be used as a hook by which to support the breath enhanced mouthpiece 100 as well as aid a user in holding the breath enhanced mouthpiece 200 during inhalation.
Referring to
Referring to
The diaphragm 218 is fixed over the exhaust aperture 221 and the intake aperture 220. It should be noted that in this particular embodiment, the intake aperture 220 is configured so that gas carrier may flow from outside the breath enhanced mouthpiece 200 and through the intake aperture 220 into the interior of the hollow body 202, and in particular, into the interior of the baffle 210. The exhaust aperture 221 is also configured so that gas carrier may flow from inside the hollow body 202 and through the exhaust aperture 221 to the exterior of the breath enhanced mouthpiece 200.
The breath enhanced mouthpiece 200 also includes a drug delivery conduit 204 with a user interface 206. A protrusion 216 for storage or to facilitate mouthpiece use is attached to the hollow body 202 near the exhaust aperture 221.
Referring to
Referring to
The drug delivery conduit 248 has a mouthpiece 236 at one end and an inflow vent 250 at the opposite end. The mouthpiece 236 may also be referred to as a user interface. At the mouthpiece 236 is a drug delivery port 238 which is an opening which leads into the interior of the drug delivery conduit 248. On the top of the drug delivery conduit 248 is an exhaust vent structure 244. The inflow vent 250 includes a guard 252 configured to prevent objects such as, for example, a user's fingers from obstructing the inflow vent 250 during use. Proximate the guard 252 is attached a handle 246.
Referring to
Referring to
Referring to
Referring to
Still referring to
The exhaust flow path 264 enters the breath enhanced mouthpiece 300 at the drug delivery port 236. The exhaust flow path 264 travels along a portion of the drug delivery conduit 248 to exit out the top of the breath enhanced mouthpiece 300 through the outlets 256 of the exhaust structure 244.
The breath enhanced mouthpiece 10 is used to illustrate operation of the various embodiments of the invention. Referring back to
When a user puts the user interface or mouthpiece 18 into his mouth and inhales, gas carrier is drawn in through the intake 34 at the top of the hollow bodied 12 and travels down the baffle 42 shaped like a conduit and out its lower end. After exiting the baffle 42, the gas carrier flow enters the aerosolization chamber or nebulizer area where it is mixed with the drug or material to be delivered. The gas carrier now entrained with the drug or material to be delivered, passes out of the aerosolization area then travels back up the hollow body 12 along the exterior of the baffle 42. The gas carrier and drug or material combination then passes through the union inlet 46 and enters the drug delivery conduit 14. The gas carrier and drug or material then travel towards the drug delivery port 16. The gas carrier and drug or material then exit the breath enhanced mouthpiece 10 at the drug delivery port 16 and enters the user's mouth to find its way into the user's respiratory system.
The other embodiments work in a similar manner, with some of the embodiments relying on a diaphragm in combination with a vent or vents to direct gas carrier along certain flow paths. For example, the inlet vent 112 shown in
As illustrated in hollow body 1912 includes a cap opening 1902 and a connection opening 1904. Hollow body 1912 has located within it an gas carrier port 1906 that defines an gas carrier intake 1908. An angled cone support 1910 and flat cone support 1920 substantially form a barrier between the cap opening 1902 and the connection opening 1904. Angled cone support 1910 connects to the hollow body 1912. Gas carrier port 1906 is connected to flat cone support 1920 to provide a passage through the flat cone support.
The gas carrier intake 1908 continues through a body cone 1914 which is connected to the flat cone support 1920. The body cone 1914 includes a cone gas carrier port 1916 defined by a cone nozzle 1922 that connects the gas carrier intake to the cap opening 1902. According to an embodiment of the invention, a source of gas carrier, such as a hose connected to an gas carrier compressor, is attached to gas carrier port 1906. Gas carrier passes through the gas carrier intake 1908 and out the body cone 1914 through the cone gas carrier port 1916.
Referring now to
Referring to
The delivery conduit 2414 and mouthpiece junction 2416 of cap 2400 include a hollow delivery opening 2422. The mouthpiece junction 2416 provides a junction for joining a mouthpiece (not shown) to delivery conduit 2414. The junction 2416 may provide the ability to permit various types of mouthpieces to be used for any given cap 2400.
Now referring to
According to an embodiment of the invention, inner trough 2410 may have a trough opening 2428 connecting inner trough 2410 to the delivery opening 2422 of delivery conduit 2414. Further, gas carrier flow passage 2412 connects via a gas carrier flow opening 2424 to delivery opening 2422. Outer trough 2408 may be substantially uniform, with no openings in outer wall 2402 or intermediate wall 2406 and therefore no connection with the delivery opening 2422 of delivery conduit 2414.
Referring to
With reference to
Intermediate wall 2406 may prevent the liquid from entering the mouthpiece if the nebulizer is shifted or moved. According to an embodiment of the invention, cap 2400 may be arranged relative to a hollow body 1912 such that the liquid is substantially located at one end of the hollow body 1912 and the cap 2400 is located at the other end of the hollow body 1912. The top 2426 is located above the liquid, leaving inner trough 2410 and outer trough 2408 open to the liquid. In this arrangement, the user draws gas carrier through the mouthpiece to inhale the gas carrier. When the hollow body 1912 is tilted and inverted, the liquid may move toward the cap 2400. Some or all of the liquid may be retained in outer trough 2408. This may prevent the liquid from entering the delivery opening 2422 of the delivery conduit 2414.
According to principles of this aspect of the invention, an outer trough 2408 formed by intermediate wall 2406 and an outer wall 2402 may contain the liquid in the event that the hollow body is tilted or inverted, thereby precluding the user from inadvertently receiving the liquid directly through the mouthpiece. In addition, the liquid may be prevented from entering the gas carrier flow opening 2424 and thus being expelled from the nebulizer. These advantages may be particularly desirable when the liquid is concentrated or expensive. Specifically, for example, the nebulizer may be used for delivery of a drug, which may be placed in the nebulizer, such as the hollow body 1912, in a concentrated form, to a user via the gas carrier flow. However, it may not be desirable to administer such a concentrated dose of the drug directly to the user. Therefore, if the drug is contained in the outer trough 2408, it may preclude the user from being inadvertently exposed to the concentrated drug through the mouthpiece. Alternatively, the drug may be expensive, and by containing the drug in the outer trough 2408, loss of the drug may be reduced or prevented if the hollow body 1912 is dropped or inverted, thereby reducing the expense of supplying an additional dose of the drug.
Ventilator cap 2800 includes a delivery conduit 2814 that defines an gas carrier flow passage 2812. Gas carrier passing through the hollow body 1912 passes through ventilator cap 2800 and through gas carrier flow passage 2812 into a ventilator system (not shown). Liquid contained within the hollow body 1912 enters the gas carrier stream and is delivered through the gas carrier flow passage of the ventilator cap 2800. The aerosolized liquid is thereby introduced into the gas carrier stream of the ventilator and administered to the user. Ventilator cap 2800 allows the hollow body 1912 to be used to administer a liquid solution or suspension containing an active ingredient, such as a drug or other chemical compound, to a user on a ventilator using inhalation techniques. This may allow patients to receive appropriate treatment regimen even if the user is otherwise unable to participate in the treatment regimen
Ventilator cap 2800 includes protrusions 2806 that protrude from the cap top 2804. While
With reference to
Aerosol cone 3102 is hollow with a cone gas carrier passage 3124 located therein. Within the cone gas carrier passage 3124, wicks 3120 are located opposite of the wick protrusions 3118. Wicks 3120, which are illustrated in
As illustrated in
Aerosol insert 3100 also includes a support ring 3104 located above the aerosol cone 3102 and supported by arms 3106. An arm support 3108 is located between arms 3106. According to an embodiment of the invention, arm support 3108 is a substantially solid piece that connects arms 3106 to each. Further, arm support 3108 connects to the arms 3106 from the point where the arms 3106 connect to the aerosol cone 3102 to a point somewhere below where the arms 3106 connect to the support ring 3104. Support ring 3104 may allow a user to handle the aerosol insert 3100 and place it or remove it from a hollow body 1912. Other types of mechanisms for handling the aerosol insert 3100 may also be used.
A cone top 3114 is located at the top of aerosol cone 3102, and is connected to arm support 3108. An arm support opening 3122 is located in the arm support 3108. As illustrated in
Suitable active ingredients of the invention may possess one or more of the following activities which may be used in any combination, for example, analgesics, anti-inflammatory agents, anthelmintics, anti-arrhythmic agents, antibiotics (including penicillins), anticoagulants, antidepressants, antidiabetic agents, antiepileptics, antihistamines, antihypertensive agents, antimuscarinic agents, antimycobacterial agents, antineoplastic agents, immunosuppressants, antithyroid agents, antiviral agents, anxiolytic sedatives (hypnotics and neuroleptics), astringents, beta-adrenoceptor blocking agents, blood products and substitutes, cardiac inotropic agents, contrast media, corticosteroids, cough suppressants (expectorants and mucolytics), diagnostic agents, diagnostic imaging agents, diuretics, dopaminergics (antiparkinsonian agents), haemostatics, immuriological agents, lipid regulating agents, muscle relaxants, parasympathomimetics, parathyroid calcitonin and biphosphonates, prostaglandins, radio-pharmaceuticals, sex hormones (including steroids), anti-allergic agents, stimulants and anoretics, sympathomimetics, thyroid agents, vasodilators and xanthines. The active ingredients are commercially available and/or may be prepared by techniques known in the art.
According to an embodiment of the invention, the active ingredient may be formulated as a liquid solution, suspension, aerosol propellant or dry powder loaded into a suitable dispenser for administration, such as the nebulizer of the invention. Furthermore, the active ingredient of the invention may be used in combination with at least one pharmaceutically acceptable carrier or excipient. Acceptable carriers or excipients are non-toxic, aid administration and do no adversely affect the therapeutic benefit of the compound. Specifically, for example, the excipient may be a gaseous excipient that is generally available to one of skill in the art.
Note that although the above example illustrates vent operation by gas carrier pressure created during inhalation and exhalation, the vents may also be actuated directly by the user, such as through opening and closing the vents with his fingers. Additionally, the vents may be operated by any vent operation mechanism well know in the art, including, for example, electronic actuation, spring actuation, etc.
It should be noted that embodiments of the invention are of dimensions scaled to facilitate use by a variety of patients of different sizes and physical conditions. Thus, embodiments are typically sized to be easily grasped, easily inserted into, and easily held in a patient's mouth.
This application is a continuation-in-part application of U.S. application Ser. No. 10/802,745, filed Mar. 18, 2004, the disclosure of which is expressly incorporated by reference herein in its entirety. This application further claims priority under 35 U.S.C. §119(c) of the U.S. Provisional Application Ser. No. 60/682,380, filed on May 19, 2005, the disclosure.
Number | Date | Country | |
---|---|---|---|
60682380 | May 2005 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10802745 | Mar 2004 | US |
Child | 11265175 | Nov 2005 | US |